In addition to NSCLC and EGFR TKIs, FAK inhibitors have also been shown to synergize with other therapeutics, including chemotherapeutic drugs in pancreatic ductal adenocarcinoma [39] and breast cancer [40], and RAF/MEK inhibitors in multiple RAS-driven solid cancers [41]. The gene discussed is MAP2K7; the disease is pancreatic ductal adenocarcinoma.